報價延遲最少15分鐘:2025/07/20 16:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.29 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.06/-4.70
|
|
企業價值
1.02B
|
| 資產負債 |
|
每股賬面淨值
5.41
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 16:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
